FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca

March 20, 2024 – FACIT’s portfolio company Fusion Pharmaceuticals is being acquired by AstraZeneca for a total transaction value of up to $2.4 billion. Congratulations to the team at Fusion for building value over the last decade that will have a lasting impact on patients with cancer and the Ontario economy.

FACIT leads seed round in Nanology Labs

May 18, 2021 – May 18, 2021 – FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.

FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology

February 4, 2021 – February 4, 2021 – FACIT’s Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations.

FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund

December 10, 2020 – December 10, 2020 – The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.

FACIT Announces Artificial Intelligence pitch as Winner of 2020 Falcons’ Fortunes on World Cancer Day

February 5, 2020 – February 5, 2020 – The winning pitch was delivered by Mr. Meir Dick of Bridge7 Oncology. This local start-up is scaling clinical expertise with AI to automate and improve the efficiency, consistency and quality of delivering cancer care.

FACIT Announces Investment in 3 Ontario Start-ups Under Prospects Fund

July 10, 2017 – Ontario start-ups Radialis Medical of Thunder Bay, KA Imaging of Kitchener, and DNAstack of Toronto are the first to receive capital from FACIT’s new Prospects Oncology Fund for proof-of-concept development of breakthrough cancer technologies.